Search Results

appropriate selection criteria (i.e., staging with CT, PET, and brain MRI showed otherwise resectable disease and only an isolated metastasis [T1–2, N0–1, M-oligo]; and surgical candidate). Using this approach, surgery for oligometastatic disease may be

of Medicine with a 4-month history of headache and peripheral visual disturbance (bitemporal hemianopsia) ( Figure 2 ). Initial brain MRI demonstrated a large enhancing suprasellar mass abutting the optic chiasm, suspicious for craniopharyngioma

through an expansile lytic lesion ( Figure 1A ). MRI showed a 4.1 x 3.1 x 5.6-cm expansile lesion involving the iliac wing with adjacent soft tissue extension and a pathologic fracture ( Figure 1B ). PET/CT showed a localized pelvic lesion ( Figure 1C

differentiated neoplasm (left) infiltrating the adjacent colonic mucosa (right). Images are 8.5 × 6 cm. Approximately 1 month postresection, MRI showed a large, vascularized, centrally necrotic mass in the left-upper quadrant (LUQ) measuring 10 × 12 × 11 cm

once daily on days 1–5, 8–12, 15–19, and 22–26 in the absence of disease progression or unacceptable toxicity. Blood samples are collected periodically for correlative laboratory studies. Patients also undergo diffusion-weighted MRI for analysis of in

image of MRI showing hypointense large soft tissue mass (3.1 × 5.3 × 5.0 cm) in the right neck (yellow arrow) while patient was receiving pazopanib prior to radiation therapy. Following radiation, the patient experienced considerable pain in her

disease in asymptomatic patients. 4 This was further demonstrated by a recent meta-analysis showing that preoperative MRI did not reduce long-term breast cancer recurrence. 5 Furthermore, increased imaging can have inadequate specificity, leading to

permitted. Active CNS metastases: untreated or treated and progressing; measurable CNS metastases: ≥10 mm in longest diameter by contrast-enhanced MRI. Table 2. Meaningful Clinical Benefit of Mobocertinib in PPP and EXCLAIM Extension Cohorts 41

margin-negative resection. 1 – 4 If we anticipate that NAT will improve outcomes over up-front resection, then we need to objectively show therapeutic responses. Traditional cross-sectional imaging modalities such as CT and/or MRI poorly predict

surveillance imaging within our institution and not through an outside provider or hospital. Frequency of unique events for CT or MRI of the chest, abdomen, and/or pelvis in the year after completion of first-line chemotherapy was calculated for patients